Semax: What the Research Actually Shows

What It Is

A Synthetic Fragment of ACTH, Without the Hormonal Activity

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide built from the 4-10 fragment of adrenocorticotropic hormone (ACTH), with a Pro-Gly-Pro tripeptide added to the end to slow its breakdown. ACTH(4-10) is the part of the ACTH molecule that sits outside the region responsible for stimulating cortisol release from the adrenal glands, so Semax carries essentially none of ACTH's classical hormonal activity while retaining central nervous system effects that researchers at the Russian Academy of Sciences (led by Ivan Ashmarin and Nikolai Myasoedov) began characterizing in the 1980s. It's formulated as an intranasal spray, a route chosen specifically to reach the central nervous system without relying on the peptide surviving oral digestion or first-pass liver metabolism. In Russia, Semax has a long history of clinical use in stroke care and for cognitive and attention complaints, though that use history reflects Russian regulatory practice and clinical tradition, not FDA review of randomized efficacy data.

The Evidence

A Well-Replicated Animal Mechanism, Thinner Human Data, and a Theoretical ADHD Proposal

Mechanism: BDNF and trkB Upregulation in the Rat Hippocampus

Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, Dubynina EV, Novosadova EV, Andreeva LA, Alfeeva LY, Kamensky AA, Grivennikov IA, Myasoedov NF, Engele J. "Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus." Brain Research. 2006;1117:54-60. doi: 10.1016/j.brainres.2006.07.108. A single intranasal dose of Semax (50 μg/kg) in rats raised hippocampal BDNF protein 1.4-fold and trkB receptor phosphorylation 1.6-fold within hours, with exon III BDNF mRNA and trkB mRNA rising 3-fold and 2-fold respectively. Treated animals also showed improved performance on a conditioned avoidance learning task. This is the clearest mechanistic anchor in the Semax literature: a specific, measurable, repeatable effect on a well-understood neurotrophic signaling pathway, in a rodent model.

Rat Model, Mechanistic · Endpoint: BDNF/trkB Expression, Conditioned Learning, Rodent Only

Acute Ischemic Stroke, Early Clinical Report

Gusev EI, Skvortsova VI, Miasoedov NF, Nezavibat'ko VN, Zhuravleva EIu, Vanichkin AV. "Effectiveness of Semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)." Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 1997;97(6):26-34. This Russian-language clinical study followed 30 patients with acute hemispheric ischemic stroke given Semax as an addition to standard intensive therapy, compared against 80 patients on standard therapy alone. Outcomes were assessed with clinical rating scales, EEG mapping, and somatosensory evoked potentials, and the Semax group showed some benefit in the rate of recovery of damaged neurological function, particularly motor deficits. The available record does not describe randomization or blinding, so this should be read as an early comparative clinical study, not a controlled trial by modern standards.

Human Clinical Study, Acute Stroke · Endpoint: Neurological Recovery, Randomization/Blinding Not Reported

Stroke Rehabilitation and BDNF Levels, a Later Clinical Study

Gusev EI, Martynov MY, Kostenko EV, Petrova LV, Bobyreva SN. "The efficacy of Semax in the treatment of patients at different stages of ischemic stroke." Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2018;118(3):61-68. doi: 10.17116/jnevro20181183261-68. A later, larger Russian clinical study of 110 post-stroke patients, divided into early- and late-rehabilitation groups, with and without Semax added to their regimen. Semax treatment increased plasma BDNF levels regardless of rehabilitation timing, and combining early rehabilitation with Semax was associated with faster functional recovery and better motor performance on the Barthel index. As with the 1997 study, the available record doesn't describe formal randomization or blinding, and this is a comparative clinical study within Russia's stroke-rehabilitation practice, not an independently verified international RCT.

Human Clinical Study, Post-Stroke Rehabilitation · Endpoint: Plasma BDNF, Functional Recovery (Barthel Index), Randomization/Blinding Not Reported

A Real Human Brain Effect, in a Small Placebo-Controlled Study

Lebedeva IS, Panikratova YR, Sokolov OY, Kupriyanov DA, Rumshiskaya AD, Kost NV, Myasoedov NF. "Effects of Semax on the Default Mode Network of the Brain." Bulletin of Experimental Biology and Medicine. 2018;165(5):653-656. doi: 10.1007/s10517-018-4234-3. This is the one Semax study in a healthy human population with an actual placebo arm: 24 healthy volunteers (11 men, 13 women, mean age 43.9) received either intranasal 1% Semax or placebo, with resting-state fMRI performed before dosing and again at 5 and 20 minutes after. The Semax group showed a measurably larger volume of the medial frontal cortex subcomponent of the brain's default mode network compared to the placebo group. This confirms Semax produces a real, detectable, dose-related change in human brain activity within minutes of intranasal dosing, useful proof that the compound reaches and affects the human CNS, though the study wasn't designed to test whether that change translates into any measurable cognitive or clinical benefit.

Human, Placebo-Controlled, Healthy Volunteers (n=24) · Endpoint: Resting-State fMRI, Default Mode Network Volume, Not a Cognitive-Outcome Study

The ADHD Idea Is a Published Hypothesis, Not a Trial Finding

Tsai SJ. "Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome." Medical Hypotheses. 2007;68(5):1144-1146. doi: 10.1016/j.mehy.2006.07.017. This single-author paper, published in a journal specifically dedicated to hypothesis-generating ideas rather than original data, reasons from Semax's known animal effects (augmenting dopamine release, stimulating BDNF synthesis) to propose that it might help ADHD, on the theory that ADHD involves disturbed dopamine and BDNF signaling. No patient was studied, no data was collected, and no clinical trial of Semax in ADHD has been published anywhere before or since. It's a plausible mechanistic argument worth knowing about, not evidence that Semax works for ADHD.

Theoretical/Hypothesis Paper · Endpoint: None, No Patients Studied, No Clinical Trial Exists for This Indication

Sources

References